drugset / Trial / NCT00553878

Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Androgen Ablation Therapy for Prostate Cancer

NCT00553878

RandomizedSingle-groupDouble-blindPrevention

Summary

Patient on an intermittent androgen deprivation protocol for biochemical recurrence after radical local therapy for prostate cancer,the addition of continuous dutasteride treatment, significantly prolongs the duration of the off treatment interval and time to androgen independence.

Timeline

Start
2007-03
Primary completion
2009-09
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dutasteride Small molecule 0.5 mg Oral

Indications